CoChat

Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults

The DOI matches its Crossref record; 37 of the 51 references it cites were found in a registry or an index.

Abstract

CONTEXT: The gastrointestinal peptide hormone, peptide YY(3-36) (PYY(3-36)), is implicated to be a postprandial satiety factor. OBJECTIVE: The aim of this study is to assess the safety, tolerability, and efficacy of intranasal PYY(3-36) to induce weight loss in obese patients. DESIGN: The study was designed as a randomized, 2-wk, single-blind placebo run-in followed by a 12-wk double-blind, placebo-controlled treatment period. SETTING: The study was set within a private and institutional practice. PATIENTS: A total of 133 obese patients (body mass index, 30-43 kg/m(2); age, 18-65 yr) participated in the study. INTERVENTION: Placebo or 200- or 600-microg PYY(3-36) was administered as an intranasal spray 20 min before breakfast, lunch, and dinner in conjunction with a hypocaloric diet and exercise. MAIN OUTCOME MEASURE: Body weight was the main outcome measure. RESULTS: The number of patients completing 12 wk on the drug was 38 of 43 (88%), 31 of 44 (70%), and 12 of 46 (26%) for placebo, 200 microg three times a day (t.i.d.) and 600 microg t.i.d., respectively. In the 600 microg t.i.d. group, 27 of 46 (59%) patients discontinued due to nausea and vomiting. Among all randomized patients who took at least one drug dose and had a postbaseline measurement, the mean body weight change from baseline was -2.8, -3.7, and -1.4 kg for placebo, 200 and 600 microg, respectively. The least squares mean difference (95% confidence interval) between placebo and 200 microg was -0.9 (-2.6, 0.7) kg (P = 0.251). A difference of 2.11 kg was sought. No meaningful inference can be drawn from the few patients who completed the study on 600 microg. CONCLUSIONS: Intranasal PYY(3-36) as administered at these intervention doses and preprandial timing is not efficacious in inducing weight loss in obese patients after 12 wk of treatment.

Overview

Integrity signals

Registry

Crossref · 10.1210/jc.2006-1806

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 37 references

Research works printed but not linked: 2

  1. Batterham, 2003, Inhibition of food intake in obese subjects by peptide YY3–36., N Engl J Med, 349, 941
  2. Wyss, 1998, 76, 363

Cited by

Items 101–163 of 163

Metadata

Authors
Gantz, I., Erondu, N., Mallick, M., Musser, B., Krishna, R., Tanaka, W. K., Snyder, K., Stevens, C., Stroh, M. A., Zhu, H., Wagner, J. A., MacNeil, D. J., Heymsfield, S. B., & Amatruda, J. M.
Affiliations
Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
Corresponding author
Gantz, Ira
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2007-05-01
Volume
92
Issue
5
Pages
1754-1757
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2118965081
Cited by
163
References
51
Citations by year
2026: 6 · 2025: 3 · 2024: 5 · 2023: 5 · 2022: 5 · 2021: 10 · 2020: 5 · 2019: 5 · 2018: 4 · 2017: 4 · 2016: 5 · 2015: 6 · 2014: 12 · 2013: 10 · 2012: 13
FWCI
10.20
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
Keywords
PYY3-36, intranasal administration, weight loss, obesity, satiety hormones, hypocaloric diet, physical activity, nausea and vomiting, drug safety and tolerability, appetite regulation, gastrointestinal hormones, obesity pharmacotherapy, dose comparison, treatment discontinuation
MeSH terms
Administration, Intranasal, Adolescent, Adult, Aged, Body Weight, Diet, Reducing, Dose-Response Relationship, Drug, Double-Blind Method, Exercise Therapy, Female, Humans, Male, Middle Aged, Obesity, Peptide Fragments, Weight Loss, Body Mass Index, Treatment Outcome, Peptide YY

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.